Please assess the completion status of the following clinical trial:

Trial Title: Panobinostat/Bortezomib/Dexamethasone in Relapsed or Relapsed-and-refractory Multiple Myeloma

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* multiple myeloma per International Myeloma Working Group 2014 definition~* requiring treatment for relapsed or relapsed/refractory disease~* measurable disease based on central protein assessment~* received 1 to 4 prior lines of therapy~* prior immunomodulatory agent(s) exposure~* acceptable lab values prior to randomization~Exclusion Criteria:~* primary refractory myeloma~* refractory to bortezomib~* concomitant anti-cancer therapy (other than bortezomib/dexamethasone and bisphosphonates)~* prior treatment with pan-deacetylase inhibitors~* clinically significant, uncontrolled heart disease and/or recent cardiac event (within 6 months prior to randomization)~* unresolved diarrhea ≥ Common Terminology Criteria for adverse events grade 2 or presence of medical condition associated with chronic diarrhea (such as irritable bowel syndrome and inflammatory bowel disease)~Other protocol-defined inclusion/exclusion criteria may apply.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Arm A - 20 mg Panobinostat TIW (Type: EXPERIMENTAL): 20 mg panobinostat TIW, 2 weeks on/1 week off in combination with subcutaneous bortezomib and per oral dexamethasone
- Arm B - 20 mg Panobinostat BIW (Type: EXPERIMENTAL): 20 mg panobinostat BIW, 2 weeks on/1 week off in combination with subcutaneous bortezomib and per oral dexamethasone
- Arm C - 10 mg Panobinostat TIW (Type: EXPERIMENTAL): 10 mg panobinostat TIW, 2 weeks on/1 week off in combination with subcutaneous bortezomib and per oral dexamethasone

Based on this trial design, predict the completion outcome and termination type (if applicable).